Pathogenetic mechanisms of antinociceptive activity of antidepressants

  • Authors: Scheidegger J.M.1, Dorovskiкh I.V.2, Pavlova T.A.2
  • Affiliations:
    1. «Национальный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского» Министерства здравоохранения Российской Федерации
    2. Федеральное государственное казенное учреждение «1586 Военный клинический госпиталь» Министерства обороны Российской Федерации
  • Issue: Vol 2, No 2 (2020)
  • Pages: 70-83
  • Section: Biomedical Sciences
  • URL: https://journals.eco-vector.com/PharmForm/article/view/34802
  • DOI: https://doi.org/10.17816/phf34802
  • Cite item

Abstract


The article attempts to generalize the currently known pathogenetic mechanisms of antinociceptive effects of the most widely used antidepressants and to highlight the currently available data of experimental models of various pain disorders in laboratory animals and the results of clinical studies both in groups of patients with comorbid
pain symptoms and in patients with pain symptoms of various origins without the presence of pronounced affective disorders. The article presents the results of evidence-based studies of the analgesic activity of tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), selective serotonin and norepinephrine reuptake inhibitors (SNRI) and drugs with a special receptor mechanism of action. The involvement of various neurotransmitters: serotonin, dopamine, norepinephrine, melatonin, enkephalin, GABA, glutamate, adenosine, etc. in the implementation of the analgesic effect of antidepressants has been examined. The most common side effects of mentioned antidepressants of frequent cause of patients refusing treatment were highlighted as well. Taking into account the considered features of the treatment of comorbid patients with pain, recommendations on the choice of the drug not only according to the severity of its antidepressant and antinociceptive actions, but also the possible development of undesirable effects of long-term therapy were made. New groups of antidepressants with an alternative mechanism of action deserve special attention.


About the authors

Julia M. Scheidegger

«Национальный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского» Министерства здравоохранения Российской Федерации

Email: Scheidegger.julia@gmail.com

Russian Federation

Igor V. Dorovskiкh

Федеральное государственное казенное учреждение «1586 Военный клинический госпиталь» Министерства обороны Российской Федерации

Author for correspondence.
Email: ig.dorovskikh@yandex.ru

Russian Federation

Tatyana A. Pavlova

Федеральное государственное казенное учреждение «1586 Военный клинический госпиталь» Министерства обороны Российской Федерации

Email: Pava-6@yandex.ru

Врач-психиатр

References

  1. Jennings L. Antidepressants / In: Grossberg G, Kinsella L (eds). Clinical Psychopharmacology for Neurologists. Cham, Springer. 2018. Р. 45-71.
  2. Крылов В.И. Антидепрессанты в общемедицинской практике. Эффективность и безопасность терапии // ФАРМиндекс-Практик. 2003. №5. С. 22-32.
  3. Свистильник Р.В. Специфические эффекты антидепрессантов и влияние их на опиоидную систему: дополнительные возможности//РАЦІОНАЛЬНА ФАРМАКОТЕРАПІЯ. 2017. № 4 (45). С.86-96.
  4. Макаров С.А., Чурюканов М.В., Чурюканов В.В. Антидепрессанты в лечении боли. //Российский журнал боли. 2016. №3-4 (51). С.74-84.
  5. Петелин Д.С. Хроническая боль и психические расстройства (обзор литературы). //Психические расстройства в общей медицине. 2019. №1. С.32–38.
  6. IsHak WW, James DM, Mirocha J, et al. Patient-reported functioning in major depressive disorder. //Ther Adv Chronic Dis. 2016. № 7(3). Р.160‐169. doi: 10.1177/2040622316639769
  7. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. //Arch Intern Med. 2003. №163(20). Р. 2433‐2445. doi: 10.1001/archinte.163.20.2433
  8. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. //Pain. 2004. №111(1-2). Р. 77‐83. doi: 10.1016/j.pain.2004.06.002
  9. Смулевич А.Б. Маскированные депрессии. //Психические расстройства в общей медицине. 2012. №3. С. 4–7
  10. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review.// J Clin Pharmacol. 2012. № 52(1). Р.6‐17. doi: 10.1177/0091270010394852
  11. Obata H. Analgesic Mechanisms of Antidepressants for Neuropathic Pain. //Int J Mol Sci. 2017. №18(11). Р.2483. doi: 10.3390/ijms18112483
  12. Маслов К.А. Антидепрессанты в России в современной клинической практике врача-психиатра. Вопросы прикладного практического применения. //Психиатрия и психофармакотерапия. 2020. № 22 (1). С. 16–22.
  13. Кокин И. В. Фармакокинетика и клиническая эффективность отечественных препаратов Амитриптилин и Флуоксетин: диссертация кандидата мед. наук. - M.2008. - 160 С.
  14. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. //Neurology. 1987. № 37(4). Р. 589‐596. doi: 10.1212/wnl.37.4.589
  15. Sierralta F, Pinardi G, Miranda HF. Effect of p-chlorophenylalanine and alpha-methyltyrosine on the antinociceptive effect of antidepressant drugs. //PharmacolToxicol. 1995. № 77(4). Р. 276‐280. doi: 10.1111/j.1600-0773.1995.tb01027.x
  16. Hamon M, Gozlan H, Bourgoin S, et al. Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. //Neuropharmacology. 1987. №26(6). Р. 531‐539. doi: 10.1016/0028-3908(87)90144-4
  17. De Felipe MC, De Ceballos ML, Gil C, Fuentes JA. Chronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat. //Eur J Pharmacol. 1985. № 112(1). Р.119‐122. doi: 10.1016/0014-2999(85)90247-x
  18. Onali P, Dedoni S, Olianas MC. Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. //J Pharmacol Exp Ther. 2010. № 332(1). Р. 255‐265. doi: 10.1124/jpet.109.159939
  19. Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. //J Psychiatry Neurosci. 2001. № 26(1). Р. 21‐29.
  20. Phillis JW, Wu PH. The effect of various centrally active drugs on adenosine uptake by the central nervous system.// CompBiochemPhysiol 1982. № 72(2). Р. 179‐187. doi: 10.1016/0306-4492(82)90082-x
  21. Sawynok J. Adenosine receptor activation and nociception. //Eur J Pharmacol. 1998. № 347(1). Р. 1‐11. doi: 10.1016/s0014-2999(97)01605-1
  22. Esser MJ, Sawynok J. Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. //Eur J Pharmacol. 2000. № 399(2-3). Р. 131‐139. doi: 10.1016/s0014-2999(00)00336-8
  23. Yokogawa F, Kiuchi Y, Ishikawa Y, et al. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. //AnesthAnalg. 2002. № 95 (1). table of contents. doi: 10.1097/00000539-200207000-00029
  24. Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A. Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. //J Anesth. 2001. №15(3). Р. 154‐158. doi: 10.1007/s005400170018
  25. İlkaya F, Bilge SS, Bozkurt A, et al. The antinociceptive effect of intravenous imipramine in colorectal distension-induced visceral pain in rats: the role of serotonergic and noradrenergic receptors. //PharmacolBiochemBehav. 2014. №122. Р. 1‐6. doi: 10.1016/j.pbb.2014.02.017
  26. Zarrindast MR, Shaverdian S, Sahebgharani M. Effect of imipramine on tolerance to morphine antinociception in the formalin test. //PharmacolToxicol. 2000. № 87(3). Р. 131‐137. doi: 10.1111/j.0901-9928.2000.870306.x
  27. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. //J Pain. 2007. № 8(4). Р. 315‐324. doi: 10.1016/j.jpain.2006.10.001
  28. Ardid D, Guilbaud G. Antinociceptive effects of acute and 'chronic' injections of tricyclic antidepressant drugs in a new model of mononeuropathy in rats.// Pain. 1992. № 49(2). Р. 279‐287. doi: 10.1016/0304-3959(92)90152-2
  29. Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies.//Pharmacol Rep. 2013. № 65(6). Р. 1611‐1621. doi: 10.1016/s1734-1140(13)71522-6
  30. Arrigo-Reina R, Chiechio S. Evidence of a key-role for histamine from mast cells in the analgesic effect of clomipramine in rats. //Inflamm Res. 1998. № 47(2). Р. 44‐48. doi: 10.1007/s000110050262
  31. Kostadinov ID, Delev DP, Kostadinova II. Antinociceptive effect of clomipramine through interaction with serotonin 5-HT2 and 5-HT3 receptor subtypes. //Folia Med (Plovdiv). 2012. № 54(4). Р. 69‐77. doi: 10.2478/v10153-012-0008-2
  32. Ardid D, Alloui A, Brousse G, et al. Potentiation of the antinociceptive effect of clomipramine by a 5-ht(1A) antagonist in neuropathic pain in rats. //Br J Pharmacol. 2001. № 132(5). Р. 1118‐1126. doi: 10.1038/sj.bjp.0703897
  33. Gatch MB, Negus SS, Mello NK. Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys. //Psychopharmacology (Berl). 1998. № 135(1). Р. 99‐106. doi: 10.1007/s002130050490
  34. Ansuategui M, Naharro L, Feria M. Noradrenergic and opioidergic influences on the antinociceptive effect of clomipramine in the formalin test in rats. //Psychopharmacology (Berl). 1989. № 98(1). Р. 93‐96. doi: 10.1007/BF00442012
  35. Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. //Drugs Aging. 1996. № 8(6). Р. 459‐476. doi: 10.2165/00002512-199608060-00008
  36. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment.// Neurology. 1995. № 45(12 Suppl 9). Р.17‐36. doi: 10.1212/wnl.45.12_suppl_9.s17
  37. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials.// J PsychiatryNeurosci. 2001. № 26(1). Р. 30‐36.
  38. Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. //Eur J Neurol. 2006. № 13(11). Р. 1153‐1169. doi: 10.1111/j.1468-1331.2006.01511.x
  39. Данилов А.Б. Золофт. Возможности клинического применения//Регулярные выпуски «РМЖ». 2007. №24 от 07.11.2007 стр. 1828 [Электронный ресурс]. - https://www.rmj.ru/archive/391/. – (дата обращения 19.06.2020)
  40. Fu Y, Yu S, Guo X, et al. Fluvoxamine increased glutamate release by activating both 5-HT(3) and sigma-1 receptors in prelimbic cortex of chronic restraint stress C57BL/6 mice. //BiochimBiophys Acta. 2012. № 1823(4). Р. 826‐837. doi: 10.1016/j.bbamcr.2012.01.008
  41. Ardid D, Marty H, Fialip J, Privat AM, Eschalier A, Lavarenne J. Comparative effects of different uptake inhibitor antidepressants in two pain tests in mice. //Fundam Clin Pharmacol. 1992. № 6(2). Р. 75‐82. doi: 10.1111/j.1472-8206.1992.tb00097.x
  42. Manjunatha CH, Ratnakar JS. A comparative study of antinociceptive effect of fluoxetine with pentazocine in rodent model // International Journal of Basic & Clinical Pharmacology. 2016. № 5 (5). P. 2267-2270
  43. Ghorbanzadeh B, Mansouri MT, Naghizadeh B, Alboghobeish S. Local antinociceptive action of fluoxetine in the rat formalin assay: role of l-arginine/nitric oxide/cGMP/KATP channel pathway. //Can J Physiol Pharmacol. 2018. № 96(2). Р. 165-172. doi: 10.1139/cjpp-2017-0003
  44. Hache G, Guiard BP, Le Dantec Y, et al. Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression. //Neuroreport. 2012. № 23(9). Р. 525-529. doi: 10.1097/WNR.0b013e328353d70a
  45. Казакова С.В., Линев А.Н., 1999. Золофт в лечении маскированных депрессий. //Ликування та диагностика. 1999. №1. С. 77 – 74
  46. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. //Obstet Gynecol. 2002. № 100(6). Р. 1219‐1229. doi: 10.1016/s0029-7844(02)02326-8
  47. Goodnick PJ, Jimenez I, Kumar A. Sertraline in diabetic neuropathy: preliminary results.// AnnClinPsychiatry. 1997. № 9(4). Р. 255‐257. doi: 10.1023/a:1022360528151
  48. Singh NN, Misra S. Sertraline in chronic tension-type headache. //J Assoc Physicians India. 2002. № 50. Р. 873‐878.
  49. Vilpoux C, Carpentier C, Leroux-Nicollet I, Naudon L, Costentin J. Differential effects of chronic antidepressant treatments on micro- and delta-opioid receptors in rat brain. //Eur J Pharmacol. 2002. № 443(1-3). Р. 85‐93. doi: 10.1016/s0014-2999(02)01585-6
  50. Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain.// J PharmacolSci. 2004. № 94(2). Р. 161‐165. doi: 10.1254/jphs.94.161
  51. Giannopoulos S, Kosmidou M, Sarmas I, et al. Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy. //Clin J Pain. 2007. № 23(3). Р. 267‐269. doi: 10.1097/AJP.0b013e31802fc14a
  52. Schreiber S, Backer MM, Yanai J, Pick CG. The antinociceptive effect of fluvoxamine.// EurNeuropsychopharmacol. 1996. № 6(4). Р. 281‐284. doi: 10.1016/s0924-977x(96)00031-4
  53. Antkiewicz-Michaluk L, Romańska I, Michaluk J, Vetulani J. Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. //Psychopharmacology (Berl). 1991. № 105(2). Р. 269‐274. doi: 10.1007/BF02244321
  54. Thériault O, Poulin H, Beaulieu JM, Chahine M. Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs. //Eur J Pharmacol. 2015. № 764. Р. 395‐403. doi: 10.1016/j.ejphar.2015.06.053
  55. Belinskaia DA, Belinskaia MA, Barygin OI, Vanchakova NP, Shestakova NN. Psychotropic Drugs for the Management of Chronic Pain and Itch. //Pharmaceuticals (Basel). 2019. № 12(2). Р. 99. Published 2019 Jun 24. doi: 10.3390/ph12020099
  56. Данилов А.Б., Данилов Ал.Б. Управление болью. Биопсихосоциальный подход. - М.: "АММ ПРЕСС", 2014. - 592 с.
  57. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. //CNS Spectr. 2005. № 10(9). Р. 732‐747. doi: 10.1017/s1092852900019726
  58. Ide S, Fujiwara S, Fujiwara M, et al. Antidepressant-like effect of venlafaxine is abolished in μ-opioid receptor-knockout mice. //J Pharmacol Sci. 2010. № 114(1). Р. 107-110. doi: 10.1254/jphs.10136sc
  59. Schreiber S., Bleich A., Pick C.G. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects–a possible opioid involvement in severe depression? // Journal of Molecular Neuroscience. 2002. № 18. P. 143-149.
  60. Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. //Am J Gastroenterol. 2010. № 105(7). Р. 1504‐1512. doi: 10.1038/ajg.2010.82
  61. Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults.// Cochrane Database Syst Rev. 2015. № 2015(8). CD011091. Published 2015 Aug 23. doi: 10.1002/14651858.CD011091.pub2
  62. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. //Neurology. 2003. № 60(8) Р. 1284‐1289. doi: 10.1212/01.wnl.0000058749.49264.bd
  63. Латышева Н.В., Филатова Е.Г. Новый механизм хронизации головной боли: патогенетическая гипотеза и ее значение для терапии. //Лечащий врач. 2008. № 5. С. 82–84.
  64. Farshchian N, Alavi A, Heydarheydari S, Moradian N. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.// CancerChemotherPharmacol. 2018. № 82(5). Р. 787‐793. doi: 10.1007/s00280-018-3664-y
  65. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. //Arthritis Rheum. 2004. № 50(9) Р. 2974‐2984. doi: 10.1002/art.20485
  66. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. //Neurology. 2006. № 67(8). Р.1411‐1420. doi: 10.1212/01.wnl.0000240225.04000.1a
  67. Kim NY, Lee SC, Kim YW. Effect of Duloxetine for the Treatment of Chronic Central Poststroke Pain. //Clin Neuropharmacol. 2019. № 42(3). Р. 73‐76. doi: 10.1097/WNF.0000000000000330
  68. Gül ŞK, Tepetam H, Gül HL. Duloxetine and pregabalin in neuropathic pain of lung cancer patients. //Brain Behav. 2020. № 10(3). Р. 01527. doi: 10.1002/brb3.1527
  69. Соловьева А.Д., Акарачкова Е.С., Торопина Г.Г. и др. Клинический опыт применения дулоксетина (симбалты) в терапии хронических кардиалгий // Лечение нервных болезней. 2007. № 3 (22). С. 26–30.
  70. Вознесенская Т.Г., Леонова А.Р., Каверина И.В. Хронические боли в нижней части спины. Опыт применения симбалты // Журнал неврологии и психиатрии им. С.С. Корсакова. 2007. Т. 107. № 7. С. 20–24.
  71. Вейн А.М., Вознесенская Т.Г., Голубев В.Л., Дюкова Г.М. Депрессия в неврологической практике. – М.: Миа, 2007. – 208 с.
  72. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. //Eur J Neurol. 2010. № 17(9). Р. 1113‐e88. doi: 10.1111/j.1468-1331.2010.02999.x
  73. Kohno T, Kimura M, Sasaki M, Obata H, Amaya F, Saito S. Milnacipran inhibits glutamatergic N-methyl-D-aspartate receptor activity in spinal dorsal horn neurons. //Mol Pain. 2012. № 8. Р. 45. Published 2012 Jun 19. doi: 10.1186/1744-8069-8-45
  74. Onal A, Parlar A, Ulker S. Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathicpain.// PharmacolBiochemBehav. 2007. № 88(2). Р. 171‐178. doi: 10.1016/j.pbb.2007.08.001
  75. Derry S, Gill D, Phillips T, Moore RA. Milnacipran for neuropathic pain and fibromyalgia in adults. //Cochrane Database Syst Rev. 2012. № 3(3). CD008244. Published 2012 Mar 14. doi: 10.1002/14651858.CD008244.pub2
  76. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. //Cochrane Database Syst Rev. 2015. № 2015(7):CD011789. Published 2015 Jul 6. doi: 10.1002/14651858.CD011789
  77. Овсянников В.Г., Бойченко А.Е., Алексеев В.В., Каплиев А.В, Алексеева Н.С., Котиева И.М., Шумарин А.Е. АНТИНОЦИЦЕПТИВНАЯ СИСТЕМА. //Медицинский вестник Юга России. 2014. № 3 С. 46-54
  78. Кукушкин М.Л., Хитров Н.К. Руководство для врачей «Общая патология боли». Москва, «Медицина», 2004. 144 С.
  79. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. ArchInternMed. 2002. № 162(1). Р. 19‐24. doi: 10.1001/archinte.162.1.19
  80. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992. № 49(2). Р. 205‐219. doi: 10.1016/0304-3959(92)90144-z
  81. Schreiber S, Pick CG. Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep?. //Med Hypotheses. 2020. № 136. Р.109501. doi: 10.1016/j.mehy.2019.109501
  82. Sikka P., Kaushik S., Kapoor S. et al. Evaluation of antinociceptive/analgesic activity of SSRIs (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazapine): An experimental study // International Journal of Nutrition, Pharmacology, Neurological Diseases. 2012. № 2 (3). P. 223-228
  83. Inal A, Büyükşekerci M, Ulusoy HB. Antinociceptive Effect of Mirtazapine in Rats with Diabetic Neuropathy. //Noro Psikiyatr Ars. 2016. № 53(1). Р. 12‐16. doi: 10.5152/npa.2015.8791
  84. Graves SM, Persons AL, Riddle JL, Napier TC. The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization. //Brain Res. 2012. № 1472. Р. 45‐53. doi: 10.1016/j.brainres.2012.07.007
  85. Tajti J, Almási J. Effects of mirtazapine in patients with chronic tension-type headache. Literature review.// Neuropsychopharmacol Hung. 2006. № 8(2). Р. 67‐72.
  86. Ottman AA, Warner CB, Brown JN. The role of mirtazapine in patients with fibromyalgia: a systematic review. //Rheumatol Int. 2018. № 38(12). Р. 2217‐2224. doi: 10.1007/s00296-018-4068-3
  87. [Электронный ресурс]: Mianserindrugbank.ca (Дата обращения 19.06.2020).
  88. Olianas MC, Dedoni S, Onali P. The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors. //Br J Pharmacol. 2012. № 167(6). Р. 1329‐1341. doi: 10.1111/j.1476-5381.2012.02078.x
  89. Herman I, Shamir D, Bar-Hamburger R, Pick CG, Schreiber S. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program--a randomized, double blind, placebo controlled, prospective study.// AddictBehav. 2005. № 30(6). Р. 1154‐1167. doi: 10.1016/j.addbeh.2004.12.004
  90. Vanchakova N.P., Rybakova K.V., Smirnov A.V., Shestakova N.N. Specific use of antidepressants of different chemical groups in patients with chronic renal failure and syndromes of itching and pain receiving chronic hemodialysis.// Nephrology (Saint-Petersburg) 2003. № 7. Р. 62–65. (InRussian)
  91. Hoshino H, Obata H, Nakajima K, Mieda R, Saito S. The antihyperalgesic effects of intrathecal bupropion, a dopamine and noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. //AnesthAnalg. 2015 № 120(2). Р. 460‐466. doi: 10.1213/ANE.0000000000000540
  92. [Электронный ресурс]: https://psychiatr.ru/news/1010 (Дата обращения 19.06.2020).
  93. Zhang R, Nagata T, Hayashi T, Miyata M, Kawakami Y. Intracerebroventricular injection of trazodone produces 5-HT receptor subtype mediated anti-nociception at the supraspinal and spinal levels.// Eur Neuropsychopharmacol. 2004. № 14(5). Р.419‐424. doi: 10.1016/j.euroneuro.2003.12.006
  94. Schreiber S, Backer MM, Herman I, Shamir D, Boniel T, Pick CG. The antinociceptive effect of trazodone in mice is mediated through both mu-opioid and serotonergic mechanisms. //Behav Brain Res. 2000. № 114(1-2). Р. 51‐56. doi: 10.1016/s0166-4328(00)00185-6
  95. Schreiber S, Backler MM, Herman I, et al. Mianserin and trazodone significantly attenuate the intensity of opioid withdrawal symptoms in mice.// AddictBiol. 2003. № 8(1). Р. 107‐114.
  96. Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. //J Am Podiatr Med Assoc. 1999. № 89(9). Р. 468‐471. doi: 10.7547/87507315-89-9-468
  97. Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, Rico-Villademoros F, Calandre EP. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study.//BMC MusculoskeletDisord. 2010. № 11. Р. 204. doi: 10.1186/1471-2474-11-204
  98. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Application.4th ed. NewYork, NewYork: Cambridge University Press. 2013. 626 Р.
  99. D'Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015. № 40(1). Р.36‐40.
  100. Zuena AR, Maftei D, Alemà GS, et al. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. //Mol Pain. 2018. № 14. Р.1744806918808987. doi: 10.1177/1744806918808987
  101. Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. //Br J Pharmacol. 2018. № 175(1). Р.113‐124. doi: 10.1111/bph.14074
  102. Adamo D, Pecoraro G, Aria M, Favia G, Mignogna MD. Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study.// PainMed. 2020. № 21(1). Р.185‐194. doi: 10.1093/pm/pnz120
  103. Kasap M, Can ÖD. Opioid system mediated anti-nociceptive effect of agomelatine in mice. //Life Sci. 2016. № 163. Р.55‐63. doi: 10.1016/j.lfs.2016.08.031
  104. Chenaf C, Chapuy E, Libert F, et al. Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.// Pain. 2017. № 158(1). Р.149‐160. doi: 10.1097/j.pain.0000000000000738
  105. Aydın TH, Can ÖD, Demir Özkay Ü, Turan N. Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms. //Fundam Clin Pharmacol. 2016. № 30(6). Р.549‐567. doi: 10.1111/fcp.12224
  106. De Berardis D, Fornaro M, Serroni N, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.// Int J MolSci. 2015. № 16(1). Р. 1111‐1130. doi: 10.3390/ijms16011111
  107. Medina Ortiz O., Rico G, Oliveros L, Sánchez-Mora N. Agomelatine adjunctive therapy for fibromyalgia.//Reumatol Clin. 2013. № 9(5). Р. 328‐329. doi: 10.1016/j.reuma.2012.12.003
  108. Calandre EP, Slim M, Garcia-Leiva JM, Rodriguez-Lopez CM, Torres P, Rico-Villademoros F. Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study. //Pharmacopsychiatry. 2014. № 47(2). Р. 67‐72. doi: 10.1055/s-0033-1363659
  109. Bruno A, Micò U, Lorusso S, et al. Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. //J Clin Psychopharmacol. 2013. № 33(4). Р. 507‐511. doi: 10.1097/JCP.0b013e31829057ae
  110. Павлова Т.А., Доровских И.В., Горобец Л.Н. Нейроэндокринные аспекты патогенеза и психофармакотерапии панического расстройства. // Психиатрия. 2016. № 72 (4). С. 55-69.
  111. Di Tommaso Morrison MC, Carinci F, Lessiani G, et al. Fibromyalgia and bipolar disorder: extent of comorbidity and therapeutic implications. //J Biol RegulHomeost Agents. 2017. № 31(1). Р.17‐20.
  112. Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L. A possible new option for migraine management: agomelatine. //Clin Neuropharmacol. 2013. № 36(2). Р. 65‐67. doi: 10.1097/WNF.0b013e3182800271
  113. Табеева Г. Р., Сергеев А. В., Громова С. В. Возможности профилактической терапии мигрени агонистом МТ1- и МТ2-рецепторов и антагонистом 5НТ2с-рецепторов – агомелатином. //Ж. «Неврология и психиатрия». 2011. № 9. С. 32–36
  114. Турбина Л. Г. Применение агомелатина в профилактической терапии мигрени. //Ж. «Неврология и психиатрия». 2014. № 2 (114). С. 56-58
  115. Саранов А. А. Вaльдоксан в лечении депрессии у больных рассеянным склерозом, страдающих цефалгиями. //Обозрение психиатрии и медицинской психологии. 2011. № 4. С. 42-44

Statistics

Views

Abstract - 104

PDF (Russian) - 13

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Pharmacy Formulas

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies